
July 8 (Reuters) - ProKidney Corp PROK.O:
PROKIDNEY REPORTS STATISTICALLY AND CLINICALLY SIGNIFICANT TOPLINE RESULTS FOR THE PHASE 2 REGEN-007 TRIAL EVALUATING RILPARENCEL IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES
PROKIDNEY CORP - NO SERIOUS ADVERSE EVENTS OBSERVED WITH RILPARENCEL TREATMENT
PROKIDNEY CORP - GROUP 1 SHOWED 78% IMPROVEMENT IN EGFR SLOPE AFTER RILPARENCEL
PROKIDNEY CORP - GROUP 2 SHOWED 50% IMPROVEMENT IN EGFR SLOPE AFTER RILPARENCEL